Roni Mamluk - 18 Mar 2026 Form 3 Insider Report for RedHill Biopharma Ltd. (RDHL)

Reporting relationship: Director
Issuer ticker: RDHL
Reported as of: 18 Mar 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 18 Mar 2026, 13:12:01 UTC
Prior SEC filing: 23 Jan 2023
Source filing: View source filing
Reporting owner signature: /s/ Roni Mamluk

Key filing fact

Roni Mamluk filed Form 3 for RedHill Biopharma Ltd. (RDHL) on 18 Mar 2026.

Key facts

This page summarizes Roni Mamluk's Form 3 filing for RedHill Biopharma Ltd. (RDHL).
0 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 18 Mar 2026, 13:12.

Change

Previous filing in this sequence was filed on 23 Jan 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001647053 Primary reporting owner

Mamluk Roni

Relationship: Director
Address: 21 HA'ARBA'A STREET, TEL AVIV, ISRAEL
Signature: /s/ Roni Mamluk
Signature date: 18 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RDHL holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 103,500,000
Date: 18 Mar 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RDHL holding Derivative

American Depositary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 613,500,000
Exercise price
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents 10,350 unvested restricted share units ("RSUs"), each with respect to one American Depositary Share ("ADS"), which represents 10,000 ordinary shares, par value NIS 0.01 per share ("Ordinary Shares"), of RedHill Biopharma Inc. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares.

Footnote F2

Represents 1,350 ADSs, which are convertible at any time, at the holder's election and have no expiration date.